



GRIN2B Blocking Peptide (C-Term)

Synthetic peptide Catalog # BP21859b

Specification

GRIN2B Blocking Peptide (C-Term) - Product Information

Primary Accession Q13224
Other Accession Q01097, Q00960

GRIN2B Blocking Peptide (C-Term) - Additional Information

Gene ID 2904

Other Names

Glutamate receptor ionotropic, NMDA 2B, GluN2B, Glutamate [NMDA] receptor subunit epsilon-2, N-methyl D-aspartate receptor subtype 2B, NMDAR2B, NR2B, N-methyl-D-aspartate receptor subunit 3, NR3, hNR3, GRIN2B, NMDAR2B

Target/Specificity

The synthetic peptide sequence is selected from aa 1320-1332 of HUMAN GRIN2B

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

GRIN2B Blocking Peptide (C-Term) - Protein Information

Name GRIN2B

Synonyms NMDAR2B

GRIN2B Blocking Peptide (C-Term) - Background

NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. In concert with DAPK1 at extrasynaptic sites, acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them, resulting in an irreversible neuronal death (By similarity).

GRIN2B Blocking Peptide (C-Term) - References

Adams S.L.,et al.Biochim. Biophys. Acta 1260:105-108(1995).
Hess S.D.,et al.J. Pharmacol. Exp. Ther. 278:808-816(1996).
Mandich P.,et al.Submitted (FEB-1997) to the EMBL/GenBank/DDBJ databases.
Mandich P.,et al.Genomics 22:216-218(1994). Schito A.M.,et al.Neurosci. Lett. 239:49-53(1997).




Function

Component of NMDA receptor complexes that function as heterotetrameric, ligand-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Channel activation requires binding of the neurotransmitter glutamate to the epsilon subunit, glycine binding to the zeta subunit, plus membrane depolarization to eliminate channel inhibition by Mg(2+) (PubMed:<a h ref="http://www.uniprot.org/citations/87687 35" target=" blank">8768735, PubMed:26919761, PubMed:26875626, PubMed:28126851). Sensitivity to glutamate and channel kinetics depend on the subunit composition (PubMed:8768735, PubMed:26875626). In concert with DAPK1 at extrasynaptic sites, acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them, resulting in an irreversible neuronal death. Contributes to neural pattern formation in the developing brain. Plays a role in long-term depression (LTD) of hippocampus membrane currents and in synaptic plasticity (By similarity).

Cellular Location

Cell membrane; Multi-pass membrane protein {ECO:0000250|UniProtKB:Q00960}. Cell junction, synapse, postsynaptic cell membrane {ECO:0000250|UniProtKB:Q00960}; Multi-pass membrane protein {ECO:0000250|UniProtKB:Q00960}. Late endosome {ECO:0000250|UniProtKB:Q01097}. Lysosome {ECO:0000250|UniProtKB:Q01097}. Cytoplasm, cytoskeleton {ECO:0000250|UniProtKB:Q01097}. Note=Co-localizes with the motor protein





KIF17 along microtubules. {ECO:0000250|UniProtKB:Q01097}

Tissue LocationPrimarily found in the fronto-parieto-temporal cortex and hippocampus pyramidal cells, lower expression in the basal ganglia.

GRIN2B Blocking Peptide (C-Term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides